ATM-AVI + MTZ + MER + COL

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Complicated Intra-abdominal Infection

Conditions

Complicated Intra-abdominal Infection, Hosptial Acquired Pneumonia, Ventilator Associated Pneumonia

Trial Timeline

Apr 5, 2018 → Feb 23, 2023

NCT ID

NCT03329092

About ATM-AVI + MTZ + MER + COL

ATM-AVI + MTZ + MER + COL is a phase 3 stage product being developed by Pfizer for Complicated Intra-abdominal Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT03329092. Target conditions include Complicated Intra-abdominal Infection, Hosptial Acquired Pneumonia, Ventilator Associated Pneumonia.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03329092	Phase 3	Completed	Apr 5, 2018	Feb 23, 2023	Complicated Intra-abdominal Infection

Competing Products

20 competing products in Complicated Intra-abdominal Infection

See all competitors

Product	Company	Stage	Hype Score
ZY19489 + Ferroquine (FQ) + Placebo	Zydus Lifesciences	Phase 1	33
HRS-8427 + Imipenem and Cilastatin Sodium + HRS-8427 placebo + Imipenem and Cilastatin Sodium placebo	Jiangsu Hengrui Medicine	Phase 3	77
HRS -8427 + Imipenem and Cilastatin Sodium	Jiangsu Hengrui Medicine	Phase 2	52
Ceftolozane/Tazobactam + Metronidazole + Meropenem + Placebo	Merck	Phase 3	77
Vancomycin + Daptomycin + Semi-Synthetic Penicillin	Merck	Approved	85
CXA-201 and metronidazole + Meropenem	Merck	Phase 3	77
CXA-101 + Ceftazidime	Merck	Phase 2	52
Ceftolozane/Tazobactam + Meropenem	Merck	Phase 2	52
Imipenem+Cilastatin/Relebactam	Merck	Phase 3	77
Daptomycin + Vancomycin	Merck	Approved	85
CXA-101/ tazobactam and metronidazole + meropenem plus saline placebo	Merck	Phase 2	52
CXA-201 + Levofloxacin	Merck	Phase 3	77
Ceftolozane/Tazobactam + Metronidazole + Meropenem + Placebo for Metronidazole	Merck	Phase 2	52
MK0826; ertapenem sodium + Comparator: ceftriaxone + metronidazole	Merck	Approved	85
MK0826, /Duration of Treatment : 8 Weeks + Comparator : piperacillin sodium (+) tazobactam sodium /Duration of Treatment : 8 Weeks	Merck	Phase 3	77
KLU156 + Coartem	Novartis	Phase 3	77
LYS228 + Standard of care therapy	Novartis	Phase 2	52
Artemether-lumefantrine (COA566)	Novartis	Phase 2/3	65
INE963	Novartis	Phase 2	52
KAE609 + SoC (Coartem) + KLU156	Novartis	Phase 2	52

Other Products from Pfizer